216 related articles for article (PubMed ID: 26067860)
21. Pathological Risk Factors and Outcomes in Women With Stage IB2 Cervical Cancer Treated With Primary Radical Surgery Versus Chemoradiotherapy.
Bradbury M; Founta C; Taylor W; Kucukmetin A; Naik R; Ang C
Int J Gynecol Cancer; 2015 Oct; 25(8):1476-83. PubMed ID: 26244756
[TBL] [Abstract][Full Text] [Related]
22. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer.
Yin Z; Lou H; Tang H; Ni J; Zhou Q; Chen M
Radiat Oncol; 2019 May; 14(1):82. PubMed ID: 31109371
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of histologic subtype in node-positive early-stage cervical cancer after hysterectomy and adjuvant radiotherapy.
Zhou J; Zhang WW; Wu SG; He ZY; Sun JY; Yang GF; Li FY
Int J Surg; 2017 Aug; 44():1-6. PubMed ID: 28583891
[TBL] [Abstract][Full Text] [Related]
25. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.
Teh J; Yap SP; Tham I; Sethi VK; Chua EJ; Yeo R; Ho TH; Tay EH; Chia YN; Soh LT; Khoo-Tan HS
Int J Gynecol Cancer; 2010 Apr; 20(3):428-33. PubMed ID: 20375809
[TBL] [Abstract][Full Text] [Related]
26. Predictors of Survival in Patients With FIGO Stage IVB Cervical Cancer.
Sasano T; Mabuchi S; Kuroda H; Takahashi R; Kozasa K; Isohashi F; Yoshioka Y; Ogawa K; Kimura T
Int J Gynecol Cancer; 2016 Mar; 26(3):528-33. PubMed ID: 26825839
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
[TBL] [Abstract][Full Text] [Related]
28. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
Binbin T; Lingying W; Manni H; Jusheng A; Ning L
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
[TBL] [Abstract][Full Text] [Related]
29. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
Lim A; Sia S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
[TBL] [Abstract][Full Text] [Related]
31. Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy.
Lin G; Yang LY; Lin YC; Huang YT; Liu FY; Wang CC; Lu HY; Chiang HJ; Chen YR; Wu RC; Ng KK; Hong JH; Yen TC; Lai CH
Eur Radiol; 2019 Feb; 29(2):556-565. PubMed ID: 30051142
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment Squamous Cell Carcinoma Antigen (SCC-Ag) as a Predictive Factor for the Use of Consolidation Chemotherapy in Cervical Cancer Patients After Postoperative Extended-Field Concurrent Chemoradiotherapy.
Zhang G; Miao L; Wu H; Zhang Y; Fu C
Technol Cancer Res Treat; 2021; 20():15330338211044626. PubMed ID: 34605696
[No Abstract] [Full Text] [Related]
33. Impact of Brachytherapy Boost and Dose-escalated External Beam Radiotherapy in Margin Positive Cervical Cancer Treated With Chemotherapy and Radiation.
Ager BJ; Torgeson A; Francis SR; Burt LM; Gaffney DK; Cannon DM
Am J Clin Oncol; 2020 Jan; 43(1):35-42. PubMed ID: 31764024
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
[TBL] [Abstract][Full Text] [Related]
35. Multicenter Retrospective Study of Adjuvant Therapy for Patients with Pathologically Lymph Node-Positive Oral Squamous Cell Carcinoma: Analysis of Covariance Using Propensity Score.
Yanamoto S; Otsuru M; Ota Y; Okura M; Aikawa T; Kurita H; Kamata T; Kirita T; Yamakawa N; Ueda M; Yamashita T; Komori T; Shigeta T; Yokoo S; Ogawa M; Umeda M;
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S992-9. PubMed ID: 26289809
[TBL] [Abstract][Full Text] [Related]
36. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.
Yokoi E; Mabuchi S; Takahashi R; Matsumoto Y; Kuroda H; Kozasa K; Kimura T
J Gynecol Oncol; 2017 Mar; 28(2):e19. PubMed ID: 28028992
[TBL] [Abstract][Full Text] [Related]
37. A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.
Wu N; Su X; Song H; Li Y; Gu F; Sun X; Li X; Cheng G
Cancer Control; 2021; 28():1073274821989307. PubMed ID: 33593091
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the efficacy of prophylactic extended field irradiation in the concomitant chemoradiotherapy treatment of locally advanced cervical cancer, stage IIIB in the 2018 FIGO classification.
Meng Q; Liu X; Wang W; Hou X; Lian X; Sun S; Yan J; Liu Z; Miao Z; Hu K; Zhang F
Radiat Oncol; 2019 Dec; 14(1):228. PubMed ID: 31842919
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
40. Therapy-free interval has prognostic value in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy.
Kozaki M; Sakuma S; Kudaka W; Kinjyo Y; Taira Y; Arakaki Y; Shimoji Y; Nakasone T; Nakamoto T; Wakayama A; Ooyama T; Aoki Y
Arch Gynecol Obstet; 2017 Nov; 296(5):997-1003. PubMed ID: 28884382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
